Harpoon Therapeutics, Inc. Common Stock
HARP
HARP was delisted on the 8th of March, 2024.
41 hedge funds and large institutions have $175M invested in Harpoon Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 14 increasing their positions, 4 reducing their positions, and 7 closing their positions.
2,229% more capital invested
Capital invested by funds: $7.53M → $175M (+$168M)
345.66% more ownership
Funds ownership: 46.4% → 392.07% (+346%)
250% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 4
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
28% more funds holding
Funds holding: 32 → 41 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$18M |
| 2 |
NLVP
New Leaf Venture Partners
New York
|
+$12.1M |
| 3 |
CC
Commodore Capital
New York
|
+$11.8M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$11.8M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$250K |
| 2 |
Renaissance Technologies
New York
|
-$95.1K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$29K |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$6.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.85K |
HARP Hedge Fund Activity: Q4 2023 in Review
41 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q4 2023, worth a combined $175M — up 2,229% from $7.53M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new HARP positions and 7 closed out — a net gain of 9 holders — while 14 added to existing stakes and 4 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $18M. The largest seller was OrbiMed, exiting entirely with an estimated $250K sold.
- 41 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q4 2023, up from 32 in Q3 2023.
- Funds reported $175M of Harpoon Therapeutics, Inc. Common Stock stock for Q4 2023, up 2,229% quarter-over-quarter.
- 16 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q4 2023 and 7 closed out, a net change of +9 holders.
- The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q4 2023 was Cormorant Asset Management, an estimated $18M added.
- The largest Harpoon Therapeutics, Inc. Common Stock seller in Q4 2023 was OrbiMed, an estimated $250K sold.
Based on aggregated 13F filings for Q4 2023.